6-氟喹啉-3-甲醛 | 1196154-66-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-氟喹啉-3-甲醛
• 英文名称: 6-fluoroquinoline-3-carbaldehyde
• 英文别名: 6-Fluoroquinoline-3-carbaldehyde
• CAS: 1196154-66-1
• 化学式: C₁₀H₆FNO
• 分子量: 175.162
• InChiKey: PUMHTKUNRZZGSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-氟喹啉-3-甲醛 在 sodium tetrahydroborate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 lithium chloride 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 2.0h， 生成 (E)-1-(6-fluoroquinolin-3-yl)-7-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)hept-en-3-ol
  参考文献：
  名称：

  [EN] FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF
  [FR] DÉRIVÉS D'ACIDE NONANOÏQUE TÉTRAHYDRONAPHTHYRIDINYLE FLUORÉS ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2016134223A3
• 作为产物：
  描述：

  2-氯-6-氟喹啉-3-甲醛 在 四(三苯基膦)钯 、 甲酸 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以43%的产率得到6-氟喹啉-3-甲醛
  参考文献：
  名称：

  [EN] FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF
  [FR] DÉRIVÉS D'ACIDE NONANOÏQUE TÉTRAHYDRONAPHTHYRIDINYLE FLUORÉS ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2016134223A3

文献信息

• FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF
  申请人：SciFluor Life Sciences, Inc.

  公开号：US20160244447A1

  公开（公告）日：2016-08-25

  The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及式I的氟化合物及其合成方法。本发明还涉及包含本发明中的氟化合物的制药组合物，以及通过将这些化合物和制药组合物用于需要治疗纤维化、黄斑退化、糖尿病视网膜病变（DR）、黄斑水肿、糖尿病性黄斑水肿（DME）和视网膜静脉阻塞后的黄斑水肿（RVO）的患者来进行治疗的方法。
• FLUORINATED INTEGRIN ANTAGONISTS
  申请人：SCIFLUOR LIFE SCIENCES, INC.

  公开号：US20160075698A1

  公开（公告）日：2016-03-17

  The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及式I的氟化合物及其合成方法。本发明还涉及含有本发明的氟化合物的药物组合物，并通过将这些化合物和药物组合物给予需要治疗黄斑变性、糖尿病视网膜病变（DR）、黄斑水肿、糖尿病性黄斑水肿（DME）和视网膜静脉阻塞后的黄斑水肿（RVO）的受试者来治疗这些疾病。
• One-Pot, Base- and Metal-Free Practical Synthesis of Novel Cycloalkene-Fused [1,4]Thiazepines through the Sequential Ugi/SNCsp2 Reactions
  作者：Ahmed Al-Harrasi、Ahmad Takallou、Sulaiman Al-Shidhani、Muhammad U. Anwar

  DOI：10.1055/a-1944-2423

  日期：2023.2

  A one-pot and sequential Ugi/SNCsp2 four-component reaction was introduced for the synthesis of cycloalkene-fused [1,4]thiazepine derivatives. A variety of cyclic β-bromovinyl aldehyde with different sizes, amines, and isocyanides were reacted with thioglycolic acid. This approach can provide a practical and rapid access to the fused bioactive cycloalkene structures containing thiazepine, and peptide unit, which proved the achievement of a significant structural diversity. Further use of this method has been successfully applied in synthesizing a variety of quinoline-fused [1,4]thiazepines with satisfactory results. The practical nature of this approach was demonstrated by a gram-scale synthesis of a selected product.

  摘要 介绍了一种用于合成环烯融合[1,4]硫氮杂卓衍生物的一锅顺序 Ugi/SNCsp2 四组分反应。多种不同大小的环β-溴乙烯基醛、胺和异氰酸酯与硫代乙醇酸发生反应。这种方法可以实用、快速地获得含有硫氮杂环庚烷和肽单元的融合生物活性环烯结构，并证明其结构具有显著的多样性。该方法还被成功用于合成多种喹啉融合的 [1,4] 硫氮杂卓，并取得了令人满意的结果。通过克级规模合成所选产品，证明了这种方法的实用性。
• Secosteroid–quinoline hybrids as new anticancer agents
  作者：Alexey I. Ilovaisky、Alexander M. Scherbakov、Valentina M. Merkulova、Elena I. Chernoburova、Marina A. Shchetinina、Olga E. Andreeva、Diana I. Salnikova、Igor V. Zavarzin、Alexander O. Terent’ev

  DOI：10.1016/j.jsbmb.2022.106245

  日期：2023.4

  An elegant approach to unknown secosteroid–quinoline hybrids is disclosed. A series of 13,17-secoestra-1,3,5(10)-trien-17-oic acid [N′-(iso)quinolylmethylene]hydrazides was prepared and these novel type of secosteroids was screened for antiproliferative activity against estrogen-responsive human breast cancer cell line MCF-7. Most of the synthesized compounds showed a cytotoxic effect superior to that

  公开了一种未知的类固醇-喹啉杂化物的优雅方法。制备了一系列 13,17-secoestra-1,3,5(10)-trien-17-oic acid [N'-(iso)quinolymethylene]hydrazides 并筛选了这些新型类固醇的抗雌激素增殖活性-反应性人乳腺癌细胞系 MCF-7。大多数合成的化合物表现出优于参比药物顺铂的细胞毒作用；先导化合物表现出最高的活性，IC 50值约为0.8 μM，是顺铂的7倍。对于命中的 13,17-secoestra-1,3,5(10)-trien-17-oic acid [N'-quinolymethylene]hydrazides 2a和2c，观察到高选择性指数。化合物2a和2c在荧光素酶报告基因测定中评估的 10 显示出优于他莫昔芬的高抗雌激素效力。这些命中化合物的特点是对 MCF-7 细胞具有高活性，而 MCF-7 细胞对多药耐药 NCI/ADR-RES
• Fluorinated integrin antagonists
  申请人：SciFluor Life Sciences, Inc.

  公开号：US10106537B2

  公开（公告）日：2018-10-23

  The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及式 I 的含氟化合物以及合成这些化合物的方法。本发明还涉及含有本发明含氟化合物的药物组合物，以及通过向有需要的受试者施用这些化合物和药物组合物来治疗黄斑变性、糖尿病视网膜病变（DR）、黄斑水肿、糖尿病黄斑水肿（DME）和视网膜静脉闭塞（RVO）后黄斑水肿的方法。